Jaime Ricardo Sevillano

Dr. Jaime Ricardo Sevillano

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAna Gabriela Lucas-Quintero
Ana Gabriela Lucas-Quintero
RDRodrigo DeAntonio
Rodrigo DeAntonio
IFIsaac Enrique Fernández
Isaac Enrique Fernández
AAAna Peralta Alvarado
Ana Peralta Alvarado
LELuis Alejandro Escobar
Luis Alejandro Escobar
JSJaime Ricardo Sevillano
Jaime Ricardo Sevillano
Background/Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We characterized self-reported maternal and neonatal events and outcomes to generate early post-introduction real-world safety evidence from Central America. Methods. This retrospective descriptive observational study included women aged 18 years or older vaccinated with RSVpreF between 32.0 and 36.6 weeks of gestation from July through December 2025 and recruited from January through July 2026. Structured telephone, virtual, or in-person interviews were used. We calculated absolute and relative frequencies and 95% Wilson confidence intervals (CIs). Results. Of 225 questionnaires obtained, 200 were eligible for analysis. Mean maternal age was 28.1 years (SD 6.4). At least one reaction was reported by 55.5% of participants, mainly local; injection-site pain was most frequent (48.0%). At least one obstetric condition was reported by 17.5%, including hypertensive disorders of pregnancy (12.0%). Preterm birth occurred in 2.0% and low birth weight in 2.5%. No fetal or neonatal deaths, thrombocytopenia, paralysis, facial paralysis, or Guillain–Barré syndrome were reported. Jaundice was the most frequent neonatal morbidity (20.0%). Conclusions. In this cohort, self-reported reactogenicity was mainly local, and no unexpected cluster of events was apparent. Participant selection, retrospective self-report, absence of an unvaccinated comparator, and sample size limit risk estimation and detection of uncommon events. The findings provide early active-pharmacovigilance evidence from Central America and support continued surveillance with clinically verified maternal and neonatal outcomes.

14 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAna Gabriela Lucas-Quintero
Ana Gabriela Lucas-Quintero
RDRodrigo DeAntonio
Rodrigo DeAntonio
LELuis Escobar
Luis Escobar
BPBelén Ricci Pérez
Belén Ricci Pérez
LFLuis Alberto Flores
Luis Alberto Flores
JSJaime Ricardo Sevillano
Jaime Ricardo Sevillano
Background/Objectives: Maternal immunization is a public health priority within Panama's Expanded Programme on Immunization (EPI), yet coverage among pregnant women remains below target and little local evidence is available on perceptions and practices among women engaged in antenatal care. We aimed to describe vaccination-related perceptions, attitudes and practices in an urban, predominantly private-care sample and to explore factors associated with acceptance. Methods: We conducted a cross-sectional study in 204 pregnant women aged ≥18 years, recruited by convenience sampling and surveyed with an anonymous, self-administered questionnaire. Vaccine acceptance was defined as having received or intending to receive at least one recommended vaccine during the current pregnancy. Participant characteristics were summarized descriptively; bivariate analyses and multivariable Poisson regression with robust variance estimated adjusted prevalence ratios (PRs) and 95% confidence intervals (CIs). Results: Acceptance was 93.1% (190/204). Most participants had higher education (88.2%) and private antenatal care (77.9%); all reported antenatal care. Healthcare professionals were the main information source (92.6%) and most trusted source (98.0%). A vaccination recommendation was reported by 84.3% of participants; 96.5% of reported recommendations came from healthcare professionals. Influenza was most frequently received (56.9%), RSV most frequently planned (51.5%), and COVID-19 most frequently refused (47.1%). Recommendation was associated with acceptance (adjusted PR 1.22; 95% CI 1.02–1.45; p = 0.029), but may reflect broader access to high-quality care. Conclusions: In this selected urban sample, acceptance was high among women engaged in antenatal care. The findings cannot characterize national acceptance; improving coverage likely requires equitable access to antenatal care, evidence-based counseling, recommendations, and vaccination opportunities.

21 September 2026 in Cureus
Verified
Journal Article
Open access
PDF file
AQAna Lucas Quintero
Ana Lucas Quintero
RDRodrigo DeAntonio
Rodrigo DeAntonio
ICIsaac Fernandez Camargo
Isaac Fernandez Camargo
AAAna Peralta Alvarado
Ana Peralta Alvarado
LELuis Escobar
Luis Escobar
AAAbigail E. De Avila
Abigail E. De Avila
Background: Panama introduced routine maternal bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination (Abrysvo, Pfizer Inc., New York, NY) in July 2025. We described common retrospectively self-reported reactions and maternal, perinatal, and neonatal conditions among the first 200 eligible recipients enrolled in active follow-up. Methods: This retrospective descriptive cohort included women aged 18 years or older who received RSVpreF at 32.0-36.6 weeks of gestation from July through December 2025 and completed one structured interview, generally after delivery, from January through July 2026. Exact vaccination-to-interview intervals were unavailable. Frequencies and Wilson 95% confidence intervals were calculated. Results: Of 225 completed questionnaires, 200 met the eligibility criteria. The mean maternal age was 28.1 years (standard deviation = 6.4). Any reaction was reported by 55.5% (95% CI: 48.6%-62.2%), most often injection-site pain (48.0%), and self-reported fever occurred in 2.5%. A participant-reported hypertensive disorder occurred in 12.0%. Four births were preterm (2.0%), and five newborns had low birth weight (2.5%). Participant-reported jaundice was the most frequent neonatal condition (20.0%). Conclusions: Reported reactions were mainly local and short-lived. These findings describe early implementation in Panama but do not assess vaccine effectiveness, comparative safety, rare-event risk, or causality. Convenience recruitment, post-delivery selection, retrospective recall, absence of clinical verification and a comparator, and missing baseline risk and event-timing data limit interpretation.

29 September 2026 in Cureus
Verified
Journal Article
Open access
AQAna Luca Quintero
Ana Luca Quintero
RDRodrigo DeAntonio
Rodrigo DeAntonio
ICIsaac Fernandez Camargo
Isaac Fernandez Camargo
AAAna Peralta Alvarado
Ana Peralta Alvarado
LELuis Escobar
Luis Escobar
JSJaime Ricardo Sevillano
Jaime Ricardo Sevillano
The affiliations for Rodrigo DeAntonio and Jaime Ricardo Sevillano Giraldez have been changed to: ‘Department of Population Intelligence and Scientific Advancement, Endpoints Research Sites Network & CEVAXIN, Panama, PAN’ and ‘Faculty of Medicine, School of Public Health, Universidad de Panamá, Panama, PAN’.

14 September 2026 in Cureus
Verified
Journal Article
Open access
PDF file
JSJaime Ricardo Sevillano
Jaime Ricardo Sevillano
GTGrace Thompson
Grace Thompson
LELuis Escobar
Luis Escobar
ICIsaac Fernández Carmago
Isaac Fernández Carmago
LFLuis Alberto Flores
Luis Alberto Flores
LFLuis Flores
Luis Flores
Background: Ageusia and anosmia are common manifestations of COVID-19. This study examined whether their frequency among infected patients was associated with the recorded number of Pfizer-BioNTech vaccine doses; it was not designed to estimate causality or vaccine effectiveness. Methods: We conducted a retrospective cross-sectional analysis of 5,348 COVID-19-positive patients over five years of age followed by the San Miguelito Health Region, Panama, from July 7, 2021, through November 2, 2022. Unvaccinated patients and vaccinated patients whose recorded doses were exclusively Pfizer-BioNTech were included. Separate logistic regression models estimated associations between vaccine dose category (zero, one, two, or three to four doses) and self-reported ageusia and anosmia, with two doses as the reference. A post hoc sensitivity analysis additionally adjusted for swab month. Results: Ageusia was reported by 507 patients (9.48%), and anosmia by 584 patients (10.92%). In the primary adjusted models, compared with two doses, adjusted odds ratios (aORs) for zero, one, and three to four doses were 1.87 (95% confidence interval (CI) 1.48-2.38), 2.68 (95% CI 1.99-3.60), and 0.26 (95% CI 0.18-0.36), respectively, for ageusia, and 1.82 (95% CI 1.46-2.27), 2.53 (95% CI 1.91-3.35), and 0.18 (95% CI 0.12-0.25), respectively, for anosmia. After categorical adjustment for swab month, all six dose-category estimates were attenuated, and none remained statistically significant. Conclusions: Primary models identified strong associations between recorded vaccine dose category and self-reported ageusia and anosmia among infected patients, but these associations did not persist after adjustment for swab month. The results are compatible with substantial confounding by epidemic period and should not be interpreted as causal effects or estimates of vaccine effectiveness.